Advertisement

Fluoroquinolones in the treatment of typhoid fever and the carrier state

  • I. Zavala Trujillo
  • C. Quiroz
  • M. A. Gutierrez
  • J. Arias
  • M. Renteria
Review

Abstract

Typhoid fever remains an important public health problem throughout the world with a higher morbidity and mortality rate in the developing countries. Early establishment of the diagnosis and prompt initiation of treatment with chloramphenicol, ampicillin or trimethoprim-sulfamethoxazole is not necessarily followed by complete resolution of the infection. Between 1 % and 6 % of patients with typhoid fever become chronic biliary carriers ofSalmonella typhi. These carriers are potential factors in the continued transmission of the disease. The increasing emergence worldwide of strains showing multiple resistance to the agents traditionally used in therapy has encouraged investigators to seek alternatives such as third generation cephalosporins and recently the new 4-quinolones, which have greater activity againstSalmonella typhi including multi-resistant strains. The fluoroquinolones seem to be the treatment of choice in those regions where resistant strains ofSalmonella typhi are prevalent.

Keywords

Ampicillin Chloramphenicol Cephalosporin Public Health Problem Fluoroquinolones 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Willis T Practice of physick. Quoted in chapter 2: History of typhoid fever. In: Huckstep RL (ed): Typhoid fever and other salmonella infections. Livingstone, Edinburgh, 1962.Google Scholar
  2. 2.
    Rice PA, Baine WB, Gangarosa EJ Salmonella typhi infections in the United States 1967–1972: increasing importance of international travelers. American Journal of Epidemiology 1977, 106: 160–166.PubMedGoogle Scholar
  3. 3.
    Edelman R, Levine MM Summary of an international workshop on typhoid fever. Reviews of Infectious Diseases 1986, 8: 329–349.PubMedGoogle Scholar
  4. 4.
    Ashcroft MT The morbidity and mortality of enteric fever in British Guyana. Western Medical Journal 1962, 11: 62–71.Google Scholar
  5. 5.
    Ferrecio C, Levine MM, Manterola A, Rodriguez G, Rivera I, Prenzel I, Black RE, Mancuso T, Bulas D Benign bacteremia caused bySalmonella typhi andparatyphi in children younger than two years. Journal of Pediatrics 1984, 104: 899–901.PubMedGoogle Scholar
  6. 6.
    Ryder RW, Blake PA Typhoid fever in the United States, 1975–1976. Journal of Infectious Diseases 1979, 139: 124–126.PubMedGoogle Scholar
  7. 7.
    Taylor DN, Pollard RA, Blake PA Typhoid in the United States and the risk to the international traveler. Journal of Infectious Diseases 1983, 148: 599–602.PubMedGoogle Scholar
  8. 8.
    Caroline AR, Nancy TH, Paul AB Salmonella typhi infection in the United States, 1975–1984: increasing role of foreign travel. Reviews of Infectious Diseases 1989, 11: 1–8.PubMedGoogle Scholar
  9. 9.
    Blaser MJ, Hickman FW, Farmer JJ, Brenner DJ, Balows A, Feldman RA Salmonella typhi, the laboratory as a reservoir of infection. Journal of Infectious Diseases 1980, 142: 934–938.PubMedGoogle Scholar
  10. 10.
    Schwalbe RS, Hoge CW, Morris JG, O'Hanlon PN, Crawford RA, Gilligan PH In vivo selection for transmissible drug resistance inSalmonella typhi during antimicrobial therapy. Antimicrobial Agents and Chemotherapy 1990, 34: 161–163.PubMedGoogle Scholar
  11. 11.
    Cohen ML, Tauxe RV Drug resistant salmonella in the United States: an epidemiological perspective. Science 1986, 234: 964–969.PubMedGoogle Scholar
  12. 12.
    Herzog CH, Geddes AM Chloramphenicol in the treatment of enteric fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 1982, 76: 848–849.CrossRefPubMedGoogle Scholar
  13. 13.
    Snyder MJ, Perroni J, Gonzalez O, Woodward WE, Palomino C, Gonzales C, Music SI, DuPont HL, Hornick RB, Woodward TE Comparative efficacy of chloramphenicol, ampicillin and cotrimoxazole in the treatment of typhoid fever. Lancet 1976, ii: 1155–1157.CrossRefGoogle Scholar
  14. 14.
    Hornick RB Typhoid fever. In: Hoeprich PF (ed): Infectious diseases. Harper and Row, Philadelphia 1983, p. 662–668.Google Scholar
  15. 15.
    Finkelstein R, Marcel A, Putterman C, Lerman A, Hashman N, Merabach D Waterborne typhoid fever in Haifa, Israel: clinical, microbiologic and therapeutic aspects of a major outbreak. American Journal of the Medical Sciences 1988, 296: 27–32.PubMedGoogle Scholar
  16. 16.
    Hoffman SL, Punjabi NH, Kumala S, Moechar A, Pulungsih SP, Rivai AE, Rockill RC, Woodward TE, Loedin AA Reduction of mortality in chloramphenicol treated severe typhoid fever with high-dose dexamethasone. New England Journal of Medicine 1984, 310: 82–88.PubMedGoogle Scholar
  17. 17.
    Abrahan G, Teklu B Typhoid fever: clinical analysis of 50 Ethiopian patients. Ethiopian Medical Journal 1981, 19: 41–46.PubMedGoogle Scholar
  18. 18.
    Jean WP, Hans G, Louisa O, Warren DJ Typhoid fever: successful therapy with cefoperazone. Journal of Infectious Diseases 1986, 153: 272–276.PubMedGoogle Scholar
  19. 19.
    Agarwal KC, Panhotra BR, Mahanta J, Arya VK, Garg RK Typhoid fever due to chloramphenicol resistantSalmonella typhi associated with R-plasmid. Indian Journal of Medical Research 1981, 73: 384–388.Google Scholar
  20. 20.
    Olarte J, Galindo E Salmonella typhi resistant to chloramphenicol, ampicillin and other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1973, 4: 597–601.PubMedGoogle Scholar
  21. 21.
    Colquhoun J, Weetch RS Resistance to chloramphenicol developing during treatment of typhoid fever. Lancet 1950, ii: 621–623.CrossRefGoogle Scholar
  22. 22.
    Ward LR, Rowe B, Threlfall EJ Incidence of trimethoprim resistance in salmonella isolated in Britain: a twelve year study. Lancet 1982, ii: 705–706.CrossRefGoogle Scholar
  23. 23.
    Datta N, Richards H, Datta C Salmonella typhi in vivo acquires resistance to both chloramphenicol and cotrimoxazole. Lancet 1981, i: 1181–1183.CrossRefGoogle Scholar
  24. 24.
    Butler T, Link N, Arnold K, Pollack M Chloramphenicol resistant typhoid fever in Vietnam associated with R-factor. Lancet 1973, ii: 983–985.Google Scholar
  25. 25.
    Gonzalez-Cortes AD, Bessuda R, Sanchez-Leyva N, Fragosa R, Hinojosa M, Becerril P Waterborne transmission of chloramphenicol resistantSalmonella typhi in México. Lancet 1973, i: 605–607.CrossRefGoogle Scholar
  26. 26.
    Lampe RM, Mansuwan P, Duagmanii C Chloramphenicol resistant typhoid. Lancet 1974, i: 623–624.CrossRefGoogle Scholar
  27. 27.
    Cohen SL, Wylic BA, Sooka A, Koornhof HJ Bacteremia caused by a lactose fermenting, multiple resistantSalmonella typhi strain in a patient recovering from typhoid fever. Journal of Clinical Microbiology 1987, 25: 1516–1518.PubMedGoogle Scholar
  28. 28.
    Goldstein FW, Chumpitaz JC, Guevara JM, Papadopoulou B, Acar JF, Viev JF Plasmid-mediated resistance to multiple antibiotics inSalmonella typhi. Journal of Infectious Diseases 1986, 153: 261–265.PubMedGoogle Scholar
  29. 29.
    Kohbata SM, Takahahashi N, Yabunchi E Lactose fermenting multiple drug-resistantSalmonella typhi strains isolated from patients with postoperative typhoid fever. Journal of Clinical Microbiology 1983, 18: 920–925.PubMedGoogle Scholar
  30. 30.
    Hoffman TA, Ruiz CJ, Counts CW Waterborne typhoid fever in Dade County, Florida: clinical and therapeutic evaluation of 105 bacteremic patients. American Journal of Medicine 1975, 59: 481–487.CrossRefPubMedGoogle Scholar
  31. 31.
    Guerra-Caceres JG, Gotuzzo-Herencia E, Crosby-Dagnino E, Micro-Quesada M, Carrillo-Parodi C Diagnostic value of bone marrow culture in typhoid fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 1970, 73: 680–683.CrossRefGoogle Scholar
  32. 32.
    Kaye D, Rocha H, Eyckmans L, Prata A, Hoot EW Comparison of parenteral ampicillin and parenteral chloramphenicol in the treatment of typhoid fever. Annals of the New York Academy of Sciences 1967, 145: 423–428.PubMedGoogle Scholar
  33. 33.
    Robertson RP, Wahab MFA, Raasch FO Evaluation of chloramphenicol and ampicillin in salmonella enteric fever. New England Journal of Medicine 1986, 278: 171–176.Google Scholar
  34. 34.
    Kamat SA Evaluation of therapeutic efficacy of trimethoprim sulfamethoxazole and chloramphenicol in enteric fever. British Medical Journal 1970, iii: 3320–3322.Google Scholar
  35. 35.
    Scragg IN, Rubidge CJ Trimethoprim and sulfamethoxazole in typhoid fever in children. British Medical Journal 1971, iii: 738–741.Google Scholar
  36. 36.
    Hamilton-Miller JMT, Brumfitt W, Reynolds AV Cefotaxime (HR-756), a new cephalosporin with exceptional broad-spectrum activity in vitro. Journal of Antimicrobial Chemotherapy 1978, 4: 437–444.PubMedGoogle Scholar
  37. 37.
    Shah PM, Troche G, Stile W In vitro activity of HR 756, a new cephalosporin compound. Journal of Antibiotics (Tokyo) 1978, 31: 1170–1174.PubMedGoogle Scholar
  38. 38.
    Chau PY, Ng WS, Ling J, Arnold K In vitro susceptibility of salmonella to various antimicrobial agents, including a new cephalosporin, Ro 13-9904. Antimicrobial Agents and Chemotherapy 1981, 19: 8–11.PubMedGoogle Scholar
  39. 39.
    Cleeland R, Squires E Antimicrobial activity of ceftriaxone: a review. American Journal of Medicine 1984, 77, Supplement 4C: 3–11.CrossRefGoogle Scholar
  40. 40.
    Aukenthaler R, Waldvogel FA In vitro activity of a new semisynthetic cephalosporin, cefoperazone. Clinical Therapeutics 1980, 3, Special Issue: 89–97.PubMedGoogle Scholar
  41. 41.
    Olarte J In vitro activity of cefoperazone against clinical isolates ofEnterobacteriaceae, Pseudomonas andStaphylococcus. Clinical Therapeutics 1980, 3, Special Issue: 130–133.PubMedGoogle Scholar
  42. 42.
    Butler T, Linh MN, Arnold K, Adichman MD, Chau DM, Muoi MM Therapy of antimicrobial resistant typhoid fever. Antimicrobial Agents and Chemotherapy 1977, 11: 645–650.PubMedGoogle Scholar
  43. 43.
    Cherubin CE, Eng RHK, Smith SM, Goldstein EJC Cephalosporin therapy for salmonellosis: question of efficacy and cross-resistance with ampicillin. Archives of Internal Medicine 1986, 146: 2149–2152.CrossRefPubMedGoogle Scholar
  44. 44.
    Garwin B, Soe G, Overturf D Treatment of typhoid fever and other systemic salmonellosis with cefotaxime, ceftriaxone, cefoperazone and other newer cephalosporins. Reviews of Infectious Diseases 1987, 4: 719–736.Google Scholar
  45. 45.
    Tulio M, Anna MM, Maria GD, Gavino F, Lino A Ceftriaxone treatment of salmonella enteric fever. Pediatric Infectious Diseases 1988, 10: 734–735.Google Scholar
  46. 46.
    Eykyn SJ, Williams H Treatment of multiresistantSalmonella typhi with oral ciprofloxacin. Lancet 1987, ii: 1407–1408.CrossRefGoogle Scholar
  47. 47.
    Jean-Jaques P Use of fluoroquinolones for intracellular pathogens. Reviews of Infectious Diseases 1989, 11, Supplement 5: 979–984.Google Scholar
  48. 48.
    Adhami ZN, Wise R, Weston D, Crump B The pharmacokinetics and tissue penetration of norfloxacin. Journal of Antimicrobial Chemotherapy 1984, 13: 87–92.PubMedGoogle Scholar
  49. 49.
    Lockley MR, Wise R, Dent J The pharmacokinetics and tissue penetration of ofloxacin. Journal of Antimicrobial Chemotherapy 1984, 14: 647–652.PubMedGoogle Scholar
  50. 50.
    Velmonte MA, Montalban CS Norfloxacin in treatment of infections caused bySalmonella typhi. Scandinavian Journal of Infectious Diseases 1988, Supplement 56: 46–48.PubMedGoogle Scholar
  51. 51.
    Gotuzzo E, Benavente L, Gerra J, Maguina C, Carrillo C: Relapse in typhoid fever. International Congress of Infectious Diseases, Rio de Janeiro, 1988, Abstract no. 496.Google Scholar
  52. 52.
    Cristiano P, Morelli G: Therapeutic role of fluoroquinolones in the therapy of typhoid fever. Western Pacific Congress on Infectious Diseases and Chemotherapy, Kuala Lumpur, 1989, Abstract OR 9/6.Google Scholar
  53. 53.
    Nalim DR, Hoagland VL, Acuña G, Bran JL, Carrillo C, Gotuzzo E, Ruiz Palacios G, Ramirez C, Guerra J: Clinical trial of norfloxacin versus chloramphenicol therapy for acute typhoid fever. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, 1987, p. 1174.Google Scholar
  54. 54.
    Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, Delgado F, Nalim DR, Sabbaj J Use of norfloxacin to treat chronic typhoid carrier. Journal of Infectious Diseases 1988, 157: 1221–1225.PubMedGoogle Scholar
  55. 55.
    Ramirez CA, Bran JL, Mejia CR, Garcia JF Open prospective study of the clinical efficacy of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1985, 28: 128–132.PubMedGoogle Scholar
  56. 56.
    Limson BM Efficacy and safety of ciprofloxacin in uncomplicated typhoid fever. In: Neu HC, Weuta H (ed): First International Ciprofloxacin Workshop. Excerpta Medica, Amsterdam, 1986, p. 362.Google Scholar
  57. 57.
    Peyramond E, Tigaud S, Lucht F, Vedrine JM, Salford F, Bertrand JL Clinical evaluation of ofloxacin in the treatment of various infections. Pathologie Biologie 1986, 34: 471–475.PubMedGoogle Scholar
  58. 58.
    Lo WL Ofloxacin in the treatment of typhoid fever, preliminary study. Journal of Antimicrobial Chemotherapy 1988, 21: 681–682.PubMedGoogle Scholar
  59. 59.
    Wang F, Gu XJ, Zhang MF, Tai TY Treatment of typhoid fever with ofloxacin. Journal of Antimicrobial Chemotherapy 1989, 23: 785–788.PubMedGoogle Scholar
  60. 60.
    Cristiano P, Morelli G, Briante V, Iovene MR, Simioli F, Altucci P Clinical experience with pefloxacin in the therapy of typhoid fever. Infection 1989, 17: 86–87.CrossRefPubMedGoogle Scholar
  61. 61.
    Isidro ZT, Arnulfo NZ, Guadalupe M, Martha R Fleroxacin in the treatment of enteric fever and salmonellosis in adults. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1118–1119.Google Scholar
  62. 62.
    Dinbar A, Altmann G, Tuleinsky DB The treatment of chronic biliary salmonella carriers. American Journal of Medicine 1969, 47: 236–242.CrossRefPubMedGoogle Scholar
  63. 63.
    White PC JR, Walls RC, Gresham EA: A review of reported cases of typhoid fever and documented carriers in Arkansas. Journal of the Arkansas Medical Society, 79: 47–49.Google Scholar
  64. 64.
    Phillips WE Treatment of chronic typhoid carriers with ampicillin. Journal of the American Medical Association 1971, 217: 913–915.CrossRefPubMedGoogle Scholar
  65. 65.
    Nolan CM, White PC Treatment of typhoid carriers with amoxicillin: correlates of successful therapy. Journal of the American Medical Association 1978, 239: 2352–2354.CrossRefPubMedGoogle Scholar
  66. 66.
    Farid Z, Bassily S, Milkhail IA, Edman DC, Hassan A, Miner WF Treatment of chronic enteric fever with amoxicillin. Journal of Infectious Diseases 1975, 132: 698–701.PubMedGoogle Scholar
  67. 67.
    Brodie J, Macquee IA, Livingstone D Effect of trimethoprim-sulfamethoxazole on typhoid and salmonella carriers. British Medical Journal 1970, iii: 318–319.Google Scholar
  68. 68.
    Munnich D, Bekesi S Curing of typhoid carriers by cholecystectomy combined with amoxicillin plus probenecid treatment. Chemotherapy 1979, 25: 362–366.PubMedGoogle Scholar
  69. 69.
    Juhani L Ciprofloxacin in the elimination of enteric salmonella carrier state. Scandinavian Journal of Infectious Diseases 1989, Supplement 60: 1112–1115.Google Scholar
  70. 70.
    DuPont HL, Corrado MK, Sabbaj J The use of norfloxacin in the treatment of acute diarrheal disease. American Journal of Medicine 1987, 82, Supplement 6B: 70–74.CrossRefPubMedGoogle Scholar
  71. 71.
    Asma I, Thomas B, Samir KN, Nurul HA, Klaus S, Harol BH, Arnold IS Randomized treatment of patients with typhoid fever by using ceftriaxone, or chloramphenicol. Journal of Infectious Diseases 1988, 158: 742–747.PubMedGoogle Scholar
  72. 72.
    Butler T, Rumans L, Arnold K Response of typhoid fever caused by chloramphenicol-susceptible and chloramphenicol resistant strains ofSalmonella typhi to treatment with trimethoprim-sulfamethoxazole. Reviews of Infectious Diseases 1982, 4: 551–561.PubMedGoogle Scholar
  73. 73.
    Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Calderon E, Vasquez V, Martinez E, Snyder MJ, Hornick RB Comparison of trimethoprim-sulfamethoxazole and amoxicillin in therapy of chloramphenicol resistant and chloramphenicol sensitive typhoid fever. Journal of Infectious Diseases 1975, 132: 630–636.PubMedGoogle Scholar
  74. 74.
    Jones RN, Thornsberry C Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Reviews of Infectious Diseases 1982, Supplement 4: 300–315.Google Scholar
  75. 75.
    Masuyoshi S, Arai S, Miyamoto M, Mitsuhashis N In vitro antimicrobial activity of cefotaxime, a new cephalosporin. Antimicrobial Agents and Chemotherapy 1980, 18: 1–8.PubMedGoogle Scholar
  76. 76.
    Clarke AM, Zemcov SJV Ro 13-9904 and Gr 20263, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1981, 7: 515–520.PubMedGoogle Scholar
  77. 77.
    Kamimura T, Matsumoto Y, Okada N, Mine Y, Nishida M, Goto S, Kuwahara S Ceftriaxone (FK 749) a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrobial Agents and Chemotherapy 1979, 16: 540–548.PubMedGoogle Scholar
  78. 78.
    Barry AL, Thornsberry RN In vitro evaluation of LY 127935 (60595) compared with cefotaxime, eight other β-lactams and two aminoglycosides. Journal of Antimicrobial Chemotherapy 1980, 6: 775–784.PubMedGoogle Scholar
  79. 79.
    Keusch GT Antimicrobial therapy for enteric infection and typhoid fever. Reviews of Infectious Diseases 1988, 10, Supplement 1: 199–205.Google Scholar
  80. 80.
    Auckenthaler R, Michea-Hamzehpour M, Pechère JC In vitro activity of newer quinolones against aerobic bacteria. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 29–30.PubMedGoogle Scholar
  81. 81.
    Hannan A In vitro activity of ofloxacin against 210 clinical isolates of typhoid salmonellae. Infection 1986, 14, Supplement 4: 243–244.CrossRefPubMedGoogle Scholar
  82. 82.
    Hol P, von Graevenitz A, Zollinger I Effects of fleroxacin in vitro on common bacteria causing diarrhea, includingVibrionaceae. Reviews of Infectious Diseases 1988, 10, Supplement 1: 209–210.Google Scholar
  83. 83.
    Ferrecio C, Morris JG, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, Levine MM Efficacy of ciprofloxacin in the treatment of chronic carriers. Journal of Infectious Diseases 1988, 157: 1235–1239.PubMedGoogle Scholar
  84. 84.
    Reid T, Smith C Ciprofloxacin treatment of chronic salmonella excretors. Chemotherapy 1987, 6, Supplement 2: 485–486.Google Scholar
  85. 85.
    Diridl G, Pichler H, Wolf D Treatment of chronic salmonella carriers with ciprofloxacin. European Journal of Clinical Microbiology 1986, 5: 260–261.PubMedGoogle Scholar
  86. 86.
    Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawfins AT, Synedor MJ Typhoid fever: pathogenesis and immunologic control. New England Journal of Medicine 1970, 283: 686–691.PubMedGoogle Scholar
  87. 87.
    Hornick RB Selective primary health care: strategies for control of disease in the developing world. Typhoid fever. Reviews of Infectious Diseases 1985, 7: 536–546.PubMedGoogle Scholar
  88. 88.
    Nord CE Effect of new quinolones on the human gastrointestinal microflora. Reviews of Infectious Diseases 1988, 10, Supplement 1: 193–196.Google Scholar

Copyright information

© Friedr, Vieweg & Sohn Verlagsgesellschaft mbH 1991

Authors and Affiliations

  • I. Zavala Trujillo
    • 1
  • C. Quiroz
    • 1
  • M. A. Gutierrez
    • 1
  • J. Arias
    • 1
  • M. Renteria
    • 1
  1. 1.Department of Infectious DiseasesDr. Angel Leano Hospital, Universidad Autónoma de GuadalajaraGuadalajaraMexico

Personalised recommendations